DOI:
10.1055/s-00035331
Revista Urología Colombiana / Colombian Urology Journal
LinksClose Window
References
Sandhu SK, Hussain M, Mateo J. , et al.
PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations.
Ann Oncol 2019;
30 (November): ix188-ix189
We do not assume any responsibility for the contents of the web pages of other providers.